Docket No. 099/004P Supplemental Information Disclosure Statement

Customer No. 22869 Appl. No. 10/805,099 January 13, 2010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of: Chunhui Xu

Serial No.: 10/805,099

Filing Date: March 19, 2004

For: PROCESS FOR MAKING

TRANSPLANTABLE CARDIOMYOCYTES FROM

HUMAN EMBRYONIC STEM CELLS

Art Unit: 1632

Examiner: Noble, Marcia Stephens

Confirmation No. 7715

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In previously filed Information Disclosure Statements, Applicants identified certain related patents and pending non-provisional patent applications owned or co-owned by Geron Corporation with claims related to cardiomyocytes derived from human embryonic stem cells. For the convenience of the Office, in this supplemental IDS, Applicants provide an updated list of related patents and applications including additional patents and applications. The tables below show the status of pending applications.

A copy of the non-patent document cited in the attached SB/08 is included in this filing.

Customer No. 22869 Appl. No. 10/805,099 January 13, 2010

It is understood that the Office has access to the full patent specifications, file histories, and other information via PAIR. However, should the Office require copies of any specifications or file histories the Office is urged to contact the undersigned. Moreover, although Applicant provides this information in an attempt to assist the Office, it is Applicants' understanding that the Examiner will conduct his/her own analysis.

Summary of related issued US cases

Docket No.	Patent No.	Title	
099/003	7,425,448	Cardiomyocyte Precursors from Human Embryonic Stem Cells	
099/031	7,452,718	Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells	

Summary of other related US cases

Docket No.	Appl. No.	Title	Status
099/001X	60/305,087	Cardiomyocyte Precursors from Human Embryonic Stem Cells	Completed
099/002X	60/322,695	Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells	Completed
099/005X	60/556,722	Cardiac Bodies: Clusters of Spontaneously Contracting Cells for Regenerating Cardiac Function	Completed
099/006D	11/040,691	Differentiation Protocol for Making Human Cardiomyocytes	Pending Final OA mailed 10/15/2009 Resp. OA filed 7/8/2009 OA mailed 1/23/2009 Resp. OA filed 10/22/2008 OA mailed 5/22/2008 Suppl. Amd. Filed 4/22/2008 Resp. OA filed 2/27/2008 Final OA mailed 11/28/2007 Resp. OA filed 9/11/2007 OA mailed 4/11/2007
099/007	11/085,899	Cardiac Bodies: Clusters of Spontaneously Contracting Cells for Regenerating Cardiac Function	Abandoned

Docket No.	Appl. No.	Title	Status
099/030X	60/650,194	Direct Differentiation of Cardiomyocytes from Human Embryonic Stem Cells	Completed
099/032C	12/210,779	Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells	Pending
099/033C	12/234,916	Differentiation Protocol for Making Human Cardiomyocytes	Pending Final OA mailed 11/20/2009 Resp. OA filed 8/27/2009 OA mailed 4/1/2009
099/040X	60/693,141	Differentiation of Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells	Completed
099/041	11/471,916	Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells	Pending Resp. OA filed 11/4/2009 OA mailed 6/4/2009
099/050X	60/853,076	Use of PP2 to Promote Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-lineage Cells	Completed

References cited on the attached PTO/SB/08 forms

The information listed in the accompanying form PTO/SB/08 and provided herewith may be material to examination of this application and is submitted in compliance with the duty of disclosure under 37 C.F.R. § 1.56. The Examiner is requested to make this information of record in the application.

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, that all relevant information has been found, or that the information provided with this Statement is considered to be material to patentability of the claimed invention as defined under 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed concurrently with a Request for Continued Examination (RCE) and therefore no fee is due. Should any other fees be required for further consideration of the application and the enclosed

Customer No. 22869 Appl. No. 10/805,099 January 13, 2010

information, the Commissioner is hereby authorized to charge such fees (or credit any overpayment) to Deposit Account 07-1139, referencing the docket number above.

Respectfully submitted,

E Short hattle

E. Stewart Mittler Reg. No. 50316

GERON CORPORATION 230 Constitution Drive Menlo Park, CA 94025 Telephone: (650) 566-7237

Fax: (650) 473-8654

January 13, 2010